Long-term outcomes of anti-VEGF therapy during cataract surgery in eyes with diabetic macular edema:a five-year retrospective cohort studyOA
AIM:To evaluate the long-term outcomes of anti-vascular endothelial growth factor(VEGF)therapy during cataract surgery in eyes with diabetic macular edema(DME).METHODS:This was a retrospective clinical study.Patients with DME scheduled for cataract surgery were included.Prior to surgery,DME was considered adequately controlled,defined as a central subfield thickness(CST)of≤300μm without evidence of significant intraretinal or subretinal fluid on optical coherence tomography.Participants were divided into two groups:18 patients underwent cataract surgery alone,and 10 received both cataract surgery and anti-VEGF therapy concurrently.The study compared the timing of the initial postoperative anti-VEGF injection and the frequency of injections over 5y.Postoperative outcomes,particularly improvements in best-corrected visual acuity(BCVA)and changes in CST,were also examined.RESULTS:A total of 28 patients were enrolled,with 10 patients undergoing combined cataract surgery and anti-VEGF therapy(3 males,62.8±4.4y),while 18 patients(7 males,70.0±13.6y)underwent cataract surgery alone.The combined therapy group had a significantly longer interval before the initial postoperative anti-VEGF injection(12.2±5.7wk)compared to the cataract-only group(4.4±1.6wk).The combined therapy group also required significantly fewer total anti-VEGF injections over 1,3,and 5y,with the most notable difference in the first year.There was significant improvement in BCVA from pre-to postoperative stages across all eyes.However,there was no statistically significant difference in postoperative BCVA and CST between the groups.CONCLUSION:Concurrent anti-VEGF therapy during cataract surgery is associated with lower early postoperative DME recurrence and a longer interval to the first postoperative anti-VEGF injection.This combined approach may reduce early treatment burden.
Xi Chen;Ai-Ai Dai;Tao-Ran Zhang;Xiu-Fen Yang;Ying-Xiang Huang
Department of Ophthalmology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,ChinaDepartment of Ophthalmology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,ChinaDepartment of Ophthalmology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,ChinaDepartment of Ophthalmology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,ChinaDepartment of Ophthalmology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China
医药卫生
diabetic macular edemacataract surgeryanti-vascular endothelial growth factor therapy
《International Journal of Ophthalmology(English edition)》 2026 (10)
P.2010-2017,8
Supported by the Capital’s Funds for Health Improvement and Research(No.CFH 2026-4-1036)Beijing Physician Scientist Training Project(No.BJPSTP-2026-26)Capital Medical University Research and Training Fund(No.PYZ25073)Beijing Friendship Hospital“Qingcai”Talent Program(No.yyqcjh2023-3).
评论